Aileron Therapeutics & Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Enters into a Clinical Collaboration to Treat Pediatric Patients with Cancer

 Aileron Therapeutics & Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Enters into a Clinical Collaboration to Treat Pediatric Patients with Cancer

Aileron Therapeutics & Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Enters into a Clinical Collaboration to Treat Pediatric Patients with Cancer

Shots:

  • The agreement involves onset of P-I trial including Pediatric Patients with solid tumors & acute leukemia receiving ALRN-6924 as a monotx & in combination with cytarabine
  • With the above two studies, an additional study will be initiated involving biomarker with the approach to improve response rates
  • ALRN-6924 is a novel dual inhibitor of MDM2/MDMX and is currently being evaluated to treat solid and hematological cancers, including AML, myelodysplastic syndrome (MDS), and peripheral T-cell lymphoma (PTCL)

Click here to read full press release/ article | Ref: Aileron |Image: Ticker Report

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post